Whalesbook
ICICI Securities has boosted its rating on Star Health and Allied Insurance to 'Outperform' and raised its price target to INR 644 from INR 570. This analyst optimism has directly fueled a rally in the company's stock. The upgrade is supported by Star Health's fiscal year 2026 results, which showed a significant 49% increase in normalized net profit and a 230 basis point improvement in its combined operating ratio. The company's strategic moves, including adjusting prices and growing its assets under management, are showing positive results in the expanding Indian health insurance market.
Despite the positive analyst outlook, Star Health's current valuation presents a significant point of discussion. Analysts at ICICI Securities are basing their target on a multiple of 22 times estimated FY28 earnings per share. However, the market is currently valuing Star Health much higher, with its trailing twelve-month price-to-earnings (P/E) ratio ranging from 39.1x to 55.5x. This high premium indicates investors expect the company to sustain very high growth rates and efficiency gains, leaving little margin for error. The stock's performance over the past year, up about 37.85% from a low of INR 348.30 in May 2025, reflects this investor optimism.
Several factors are driving Star Health's performance. The company achieved robust 37% year-on-year growth in its retail business for FY26. It has also strategically repriced around 80% of its portfolio by the first quarter of fiscal year 2027. Assets under management in equity grew substantially to 18.5% by March 2026, while its expense ratio remained within regulatory limits at 30.5%. The broader Indian health insurance sector is expanding rapidly, boosted by rising awareness and government initiatives. Yet, challenges remain, most notably medical inflation, estimated at 14% annually, which could increase claims costs and pressure profits.
Star Health's elevated valuation, trading at over 55 times earnings, stands out when compared to rivals like ICICI Lombard (around 31.6x P/E) and Go Digit (around 51.7x P/E). This premium valuation may not fully account for industry risks. While repricing can boost short-term profits, it could affect customer loyalty and market share as competition heats up. Standalone health insurers and other private players are increasing their presence. Medical inflation could outpace price adjustments, impacting underwriting profits. Although Star Health reported an improved combined ratio of 98.8% for FY26, any increase above 100% could trigger investor concern, especially given the current stock price.
Looking ahead, the Indian health insurance market is projected for significant growth, potentially reaching USD 39.5 billion by 2032. Analysts at Motilal Oswal forecast Star Health to maintain its leadership in the retail segment, expecting a 32% annual growth in profit after tax through FY28. The company's strong solvency ratio of 205% as of March 31, 2026, offers a solid financial cushion. Continued adoption of digital tools and regulatory streamlining are expected to further enhance market reach and operational efficiency.